<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503227</url>
  </required_header>
  <id_info>
    <org_study_id>1199012</org_study_id>
    <nct_id>NCT03503227</nct_id>
  </id_info>
  <brief_title>The Value of Prednisolone With Aspirin Before Embryo Transfer in Intracytoplasmic Sperm Injection (ICSI) Cycles</brief_title>
  <official_title>The Value of Addition of Prednisolone to Acetylsalicylic Acid Prior to Embryo Transfer in Patients With First ICSI Cycles: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, double-blind, randomized controlled trial . It includes 250&#xD;
      infertile patients scheduled for ICSI cycle. The patients will be randomly allocated into two&#xD;
      equal groups; daily oral low dose Acetylsalicylic acid and group B patients will receive&#xD;
      daily oral low dose Acetylsalicylic acid and Low dose prednisolone. All 250 participants&#xD;
      undergo similar ICSI cycles. Primary outcome is clinical pregnancy rate per cycle. Secondary&#xD;
      outcomes include number of oocytes retrieved, fertilization rate, number of embryos, embryo&#xD;
      quality, chemical pregnancy rate, twins rate and miscarriage rate per cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, randomized, controlled trial. Patients undergoing ICSI for their&#xD;
      first cycle are enrolled in this study. Participants are then randomized into two groups ;&#xD;
      group A patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and group B&#xD;
      patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose&#xD;
      prednisolone (10 mg/day).&#xD;
&#xD;
      Randomization will be done by withdrawing closed envelopes for each patient .&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
      Women in reproductive age diagnosed with infertility for ICSI, female age (18- &lt;40 years,&#xD;
      normal serum hormonal profile on day 3 of the cycle [including estradiol (E2), follicle&#xD;
      stimulating hormone (FSH), Luteinizing hormone (LH), prolactin, thyroid stimulating hormone,&#xD;
      normal uterine cavity diagnosed at hysteroscopy.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Women with platelet dysfunction, thrombocytopenia, gastrointestinal ulcers, recurrent&#xD;
           gastritis, Acetylsalicylic acid hypersensitivity, patients on corticosteroids will be&#xD;
           excluded from the study.&#xD;
&#xD;
        -  Also women with known cause for recurrent miscarriage: antiphospholipid syndrome,&#xD;
           abnormal thyroid function tests, parental balanced translocation or uterine anomaly&#xD;
           (known subseptate uterus or cervical weakness diagnosed at hysteroscopy).&#xD;
&#xD;
        -  Contraindications to steroid therapy: hypertension, diabetes, mental health problems or&#xD;
           obesity with Body mass index (BMI) &gt;35&#xD;
&#xD;
        -  Decline consent to randomization&#xD;
&#xD;
      Methodology in details:&#xD;
&#xD;
      All patients will be subjected to the following:&#xD;
&#xD;
        -  -Informed consent after explaining the aim of the study, procedure and possible hazards.&#xD;
&#xD;
        -  -History taking includes full obstetric history, medical and surgical history and&#xD;
           demographic distribution.&#xD;
&#xD;
        -  Full physical examination. -&#xD;
&#xD;
        -  -Ultrasound examination (2D): Transvaginal sonography (TVS) is done on day 2 to 5 to&#xD;
           assess antral follicle count (AFC), uterus and adnexa .&#xD;
&#xD;
        -  -Each group will start intake of Acetyl-Salicylic Acid (ASA) or ASA with Prednisolone on&#xD;
           day 19th - 20th of the previous cycle and continue until confirmation of pregnancy by&#xD;
           detection of fetal heart activity on ultrasound.&#xD;
&#xD;
        -  -Long protocol steps:&#xD;
&#xD;
             -  Start from day 19th - 20th by GnRH agonist ;Triptorelin 0.1mg subcutaneous&#xD;
                (Decapeptyl, Ferring). -1st visit : after 2 weeks of start of GnRH agonist or day 2&#xD;
                of cycle, we confirm down regulation by a serum level of E2to be &lt;50 pg/ml,&#xD;
                endometrial thickness &lt;5mm, no ovarian cyst by ultrasound. Then we add&#xD;
                Gonadotropins as Intramuscular (I.M.) injections of 150-300 I.U. of highly purified&#xD;
                Human Menopausal Gonadotropins daily (Merional, 75 I.U. /vial, IBSA). The dose is&#xD;
                adjusted according to the age, BMI, AFC, serum levels of anti-mullerian hormone&#xD;
                (AMH), follicle stimulating hormone (FSH) and ovarian response.&#xD;
&#xD;
             -  2nd visit : on 6th - 7 th days of Gonadotrophins and then every other day to do&#xD;
                folliculometry by TVS and E2 level in serum.&#xD;
&#xD;
             -  We do trigger by Human Chorionic Gonadotrophin (HCG)10000 IU I.M.(Pregnyl, Organon)&#xD;
                when at least 3 follicles reach 18mm in mean diameter or more and E2 level is less&#xD;
                than 2500 pg/ml. Ovum pickup is done 34 hours after HCG injection and embryo&#xD;
                transfer using Wallace catheter on day 2 to 3.&#xD;
&#xD;
        -  -Luteal support: Natural Progesterone 400 mg 1x2, Folic acid once daily,&#xD;
           Amoxicillin-Clavulanic Acid 1gm 1x2x7 ,Progesterone 100mg I.M. daily for 10 days,&#xD;
           Acetylsalicylic Acid once daily&#xD;
&#xD;
        -  -Quantitative ÃŸ- HCG in serum after 14 days of embryo transfer. -TVS to detect clinical&#xD;
           pregnancy at 6-7 weeks of gestation.&#xD;
&#xD;
      Primary outcome:&#xD;
&#xD;
      The primary outcome is clinical pregnancy rate per cycle.&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Secondary outcome measures are number of oocytes retrieved, fertilization rate, number of&#xD;
      embryos, embryo quality, chemical pregnancy rate, twins rate and miscarriage rate per cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 23, 2018</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical pregnancy rate per cycle.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Detection of gestational sac , embryo pole and fetal pulsations by transvaginal ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of oocytes retrieved per cycle.</measure>
    <time_frame>3 weeks</time_frame>
    <description>number of oocytes retrieved during ovum pickup per cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertilization rate per cycle.</measure>
    <time_frame>3weeks</time_frame>
    <description>The number of oocytes fertilized by intracytoplasmic sperm injection per cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of embryos per cycle.</measure>
    <time_frame>3weeks</time_frame>
    <description>number of embryos of any grade ( first, second, third or fourth grade) per cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo quality per cycle.</measure>
    <time_frame>3weeks</time_frame>
    <description>embryo quality by grade ( first, second, third or fourth) per cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chemical pregnancy rate per cycle.</measure>
    <time_frame>5 weeks</time_frame>
    <description>Positive beta hCG in serum per cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>twins rate per cycle.</measure>
    <time_frame>9 weeks</time_frame>
    <description>Detection of 2 gestational sacs with positive fetal poles and pulsations per cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage rate per cycle.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Early pregnancy loss per cycle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin and prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive daily oral low dose Acetylsalicylic acid (75 mg) and Low dose prednisolone (10 mg/day) starting day 20 of the previous cycle withGonadotrophin releasing hormone agonist (GnRH agonist).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <description>daily oral low dose prednisolone (10 mg/day) :a glucocorticoid</description>
    <arm_group_label>Aspirin and prednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl Salicylic acid</intervention_name>
    <description>daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Aspirin and prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women in reproductive age diagnosed with infertility for IVF/ICSI, female age (18- &lt;40&#xD;
             years, normal serum hormonal profile on day 3 of the cycle [including estradiol (E2),&#xD;
             FSH, LH, prolactin, thyroid stimulating hormone, normal uterine cavity diagnosed at&#xD;
             hysteroscopy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with platelet dysfunction, thrombocytopenia, gastrointestinal ulcers, recurrent&#xD;
             gastritis, Acetylsalicylic acid hypersensitivity, patients on corticosteroids will be&#xD;
             excluded from the study.&#xD;
&#xD;
          -  Also women with known cause for recurrent miscarriage: antiphospholipid syndrome&#xD;
             (positive anticardiolipin antibody or lupus anticoagulant on 2 separate occasions at&#xD;
             least 6 weeks apart), thrombophilia (factor V Leiden mutation, activated protein C&#xD;
             resistance (APCR) resistance, protein C or S deficiency, prothrombin gene mutation,&#xD;
             antithrombin III deficiency), abnormal thyroid function tests, parental balanced&#xD;
             translocation or uterine anomaly (known subseptate uterus or cervical weakness&#xD;
             diagnosed at hysteroscopy).&#xD;
&#xD;
          -  Contraindications to steroid therapy: hypertension, diabetes, mental health problems&#xD;
             or obesity with BMI &gt;35&#xD;
&#xD;
          -  Decline consent to randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amira S Dieb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KasrAlainiH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KasralainiH</name>
      <address>
        <city>Cairo</city>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Amira S Dieb</investigator_full_name>
    <investigator_title>Ob/Gyn Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

